CytomX Therapeutics (CTMX) Accumulated Expenses (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Accumulated Expenses data on file, last reported at $3.9 million in Q1 2026.

• Quarterly Accumulated Expenses fell 65.77% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 65.77% YoY) and the FY2025 annual result came in at $14.2 million, up 450.7% from the prior year.
• Accumulated Expenses slipped to $3.9 million in Q1 2026, from $14.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $31.7 million in Q2 2022 to a low of $2.6 million in Q4 2024.
• A 5-year average of $13.7 million and a median of $12.4 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 85.35% — and 2025, when it surged 450.7%.
• Tracing CTMX's Accumulated Expenses over 5 years: stood at $8.1 million in 2022, then soared by 118.35% to $17.6 million in 2023, then sank by 85.35% to $2.6 million in 2024, then surged by 450.7% to $14.2 million in 2025, then tumbled by 72.5% to $3.9 million in 2026.
• The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $14.2 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.